RxDoctor Payments Data

Brian Delvecchio, DO

Rheumatology · Wilkes Barre, PANPI 1215993613

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $84,788 of the $89,625 with a category attached, or 94.6%. Amgen accounts for 82.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $48,174 and has fallen 98.3% since, to $800 in 2024. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,625in general payments, 2019–2025

Across 94 payments — averaging $953.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$74K
  • AbbVie$16K
  • Sanofi-aventis U.S. LLC$125
  • UCB, Inc.$103

What the payments were for

  • Speaking & faculty fees$84,78895%
  • Travel & lodging$2,5383%
  • Food & beverage$2,2933%
  • Education$70%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen69$73,725
AbbVie21$15,672
Sanofi-aventis U.S. LLC1$125
UCB, Inc.3$103

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,625 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,133
Medicare patients
336
Services billed
2,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept34$246,129
OtezlaApremilast33$154,059
Humira(Cf) PenAdalimumab22$149,033
Humira PenAdalimumab20$146,603
RinvoqUpadacitinib17$132,365
Actemra ActpenTocilizumab17$72,578
Xeljanz XrTofacitinib Citrate12$67,528
Hydroxychloroquine Sulfate469$15,785
Mycophenolate Mofetil22$12,052
Leflunomide73$4,090
Colchicine97$4,033
MethotrexateMethotrexate Sodium149$3,151
Prednisone354$2,748
Methylprednisolone52$1,514
Allopurinol81$994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$73,725$154,05933 claims
AbbVieRinvoq$15,672$132,36517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →